Lacourcière Y[au] - Search Results

Year	Number of Results
1971	1
1973	2
1974	3
1975	2
1977	1
1978	1
1982	1
1985	1
1986	4
1987	2
1988	8
1989	9
1990	8
1991	9
1992	9
1993	11
1994	9
1995	7
1996	2
1997	3
1998	8
1999	5
2000	4
2001	3
2002	7
2003	8
2004	6
2005	6
2006	3
2007	8
2008	3
2009	5
2010	4
2011	2
2012	3
2013	2
2014	1
2022	0

1

Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: a randomised, double-blind, placebo-controlled, active comparator study.

Ruilope LM, Dukat A, Böhm M, Lacourcière Y, Gong J, Lefkowitz MP. Ruilope LM, et al. Among authors: lacourciere y. Lancet. 2010 Apr 10;375(9722):1255-66. doi: 10.1016/S0140-6736(09)61966-8. Epub 2010 Mar 16. Lancet. 2010. PMID: 20236700 Clinical Trial.

2

Telmisartan or valsartan alone or in combination with hydrochlorothiazide: a review.

Lacourcière Y. Lacourcière Y. Clin Exp Hypertens. 2013;35(1):50-60. doi: 10.3109/10641963.2012.690468. Epub 2012 Aug 6. Clin Exp Hypertens. 2013. PMID: 22866964 Review.

3

β-Blockers in hypertension: studies and meta-analyses over the years.

Larochelle P, Tobe SW, Lacourcière Y. Larochelle P, et al. Among authors: lacourciere y. Can J Cardiol. 2014 May;30(5 Suppl):S16-22. doi: 10.1016/j.cjca.2014.02.012. Epub 2014 Feb 25. Can J Cardiol. 2014. PMID: 24750978 Free article. Review.

4

Valsartan plus hydrochlorothiazide for first-line therapy in hypertension.

Lacourcière Y, Poirier L, Samuel R. Lacourcière Y, et al. Expert Rev Cardiovasc Ther. 2009 Dec;7(12):1491-501. doi: 10.1586/erc.09.140. Expert Rev Cardiovasc Ther. 2009. PMID: 19954310 Review.

5

The evolving role of β-adrenergic receptor blockers in managing hypertension.

Poirier L, Lacourcière Y. Poirier L, et al. Among authors: lacourciere y. Can J Cardiol. 2012 May;28(3):334-40. doi: 10.1016/j.cjca.2012.04.001. Can J Cardiol. 2012. PMID: 22595449 Review.

6

Modulation of the renin-angiotensin-aldosterone system and cough.

Lacourcière Y, Lefebvre J. Lacourcière Y, et al. Can J Cardiol. 1995 Aug;11 Suppl F:33F-39F. Can J Cardiol. 1995. PMID: 7664216 Review.

7

Chronotherapeutics: are there meaningful differences among antihypertensive drugs?

Poirier L, Lefebvre J, Lacourciere Y. Poirier L, et al. Among authors: lacourciere y. Curr Hypertens Rep. 1999 Aug;1(4):320-7. doi: 10.1007/s11906-999-0040-7. Curr Hypertens Rep. 1999. PMID: 10981084 Review.

8

Treatment of prostate cancer with gonadotropin-releasing hormone agonists.

Labrie F, Dupont A, Bélanger A, St-Arnaud R, Giguère M, Lacourcière Y, Emond J, Monfette G. Labrie F, et al. Among authors: lacourciere y. Endocr Rev. 1986 Feb;7(1):67-74. doi: 10.1210/edrv-7-1-67. Endocr Rev. 1986. PMID: 3514203 Review.

9

Methodology to determine duration of action for antihypertensive drugs.

Lefebvre J, Poirier L, Lacourcière Y. Lefebvre J, et al. Among authors: lacourciere y. Ann Pharmacother. 2002 May;36(5):874-81. doi: 10.1345/aph.10367. Ann Pharmacother. 2002. PMID: 11978167 Review.

10

Vascular smooth muscle cell proliferation and its therapeutic modulation in hypertension.

Hadrava V, Kruppa U, Russo RC, Lacourcière Y, Tremblay J, Hamet P. Hadrava V, et al. Among authors: lacourciere y. Am Heart J. 1991 Oct;122(4 Pt 2):1198-203. doi: 10.1016/0002-8703(91)90939-f. Am Heart J. 1991. PMID: 1927887 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results